Cell Therapeutics may finally get win for embattled pixantrone in April 2012
This article was originally published in Scrip
Executive Summary
Shares of Cell Therapeutics soared as high as 24.3% on 6 December on word that the US FDA accepted the firm's resubmission of its application for pixantrone as a single-agent treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy – setting 24 April 2012 as the new Prescription Drug User Fee Act action date.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.